Last reviewed · How we verify
NCT04304404: BrCaRRP
Risk Reduction Program for Women Having High Risk of Breast Cancer
NA trial testing Breast Cancer Risk Reduction Program (BrCaRRP) in Cancer Screening in 77 participants. Completed in 1 September 2021.
30 May 2021
Quick facts
| Lead sponsor | Akdeniz University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | screening |
| Enrollment | 77 |
| Start date | 1 April 2018 |
| Primary completion | 30 May 2021 |
| Estimated completion | 1 September 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Breast Cancer Risk Reduction Program (BrCaRRP)
Conditions studied
- Cancer Screening — all drugs for Cancer Screening →
- Early Detection of Cancer — all drugs for Early Detection of Cancer →
- Breast Cancer — all drugs for Breast Cancer →
- Preventive Health Care — all drugs for Preventive Health Care →
Sponsor
Akdeniz University
Who can join
Adults 25 to 70, female only, with Cancer Screening or Early Detection of Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An intervention program involving education, guidance, counseling, case management and surveillance based on the Health Belief Model will be implemented on women with high risk of breast cancer. The impact of the breast cancer risk reduction program on participation in breast cancer screenings, health beliefs (health motivation, sensitivity, fear of breast cancer) and behaviors (physical activity, nutrition, health responsibility, genetic counseling) will be evaluated in the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04304404
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer Screening
Currently open trials in the same condition.
- NCT06838689 — Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involv · NA · recruiting
- NCT07087834 — Men's Perceptions, Attitudes, and Knowledge Levels Toward Cancer Screening · NA · active not recruiting
- NCT07075731 — Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy · recruiting
- NCT07358715 — Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals · NA · recruiting
- NCT06371469 — Program of Health Behaviour Against to Cancer (PHeBAC) · NA · recruiting
Other Akdeniz University trials
Trials by the same sponsor.
- NCT07581132 — Investigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients · NA · not yet recruiting
- NCT07469345 — Bruxism, Pelvic Pain, Erectile Dysfunction, and Anxiety in Young Adult Men · enrolling by invitation
- NCT07507279 — Technology-based Hand Rehabilitation in Older People · NA · not yet recruiting
- NCT07437924 — Bruxism and Pelvic Floor Dysfunction in Young Women · enrolling by invitation
- NCT07497308 — GDF-15 and Early Outcomes After LVAD Implantation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04304404 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akdeniz University
- Last refreshed: 19 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04304404.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing